We also found regorafenib significantly reduces tumor growth, NF‐κB activation, and protein levels of tumor progression‐associated proteins (MMP‐9, XIAP, VEGF, and Cyclin‐D1) in bladder cancer in vitro and in vivo. The gene discussed is XIAP; the disease is urinary bladder cancer.